MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial

    D. Weiss, G. Naros, C. Meisner, R. Krüger, A. Gharabaghi (Tübingen, Germany)

    Objective: 54 patients with idiopathic Parkinson's disease and freezing of gait resistant to subthalamic nucleus stimulation and dopaminergic medication will be included into this German-wide…
  • 2016 International Congress

    KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia

    S.A. Factor, R.A. Hauser, S. Siegert, G.S. Liang, C.F. O'Brien (Atlanta, GA, USA)

    Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…
  • 2016 International Congress

    RE-024: Mechanism of action and efficacy in non-clinical models

    M. Beconi, E. Monteagudo, A. Di Marco, S. Malancona, D. Elbaum, S. Harper (San Diego, CA, USA)

    Objective: To confirm the mechanism of action of RE-024, and evaluate its activity in human cellular models and brain penetration in animal models. Background: Pantothenate…
  • 2016 International Congress

    Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…
  • 2016 International Congress

    Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
  • 2016 International Congress

    Apraclonidine in the treatment of ptosis

    S. Wijemanne, D. Vijayakumar, J. Jankovic (Houston, TX, USA)

    Objective: To describe the improvement in ptosis with apraclonidine in patients with botulinum toxin (BoNT) induced ptosis. Background: Ptosis is a manifestation of a variety…
  • 2016 International Congress

    The systemic synuclein sampling study (S4)

    D. Jennings, C. Coffey, T. Beach, T. Foroud, C.H. Adler, B. Mollenhauer, J. Seibyl, D. Ecklund, S. Lasch, V. Arnedo, C. Kopil (New Haven, CT, USA)

    Objective: The Systemic Synuclein Sampling Study (S4) is designed to characterize the distribution of alpha-synuclein (α-syn) pathology in multiple tissues and biofluids in Parkinson's disease…
  • 2016 International Congress

    Active movement discrimination of the ankle in Parkinson’s disease

    H.E. Teasdale, E.A. Preston, G. Waddington (Canberra, Australia)

    Objective: To determine (1) whether people with Parkinson's disease (PD) experience an impaired sense of proprioception in the ankles and (2) if this relates to…
  • 2016 International Congress

    Applicability study of a multitask cognitive and motor exercise program for individuals with Parkinson´s disease: The COGWEB CNS Move Program

    J. Domingos, D. Peralta, R. Loureiro, C. Ribeiro, V.T. Cruz, J. Ferreira (Torres Vedras, Portugal)

    Objective: To test the applicability of a new rehabilitation program for people with Parkinson´s disease combining web-based cognitive training with motor exercises. Background: Parkinson´s disease…
  • 2016 International Congress

    Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD)

    K. Dashtipour, J.J. Chen, L. Massihi, S. Tashiro, K. Frei (Loma Linda, CA, USA)

    Objective: To conduct a systematic review to evaluate the efficacy, safety, and dosing range of quetiapine for the treatment for hallucinosis / psychosis in patients…
  • « Previous Page
  • 1
  • …
  • 1548
  • 1549
  • 1550
  • 1551
  • 1552
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley